GLP-1ClinicsNearMe

Weight Loss Clinics in Scottsdale, Arizona

Looking for a weight loss clinic that prescribes GLP-1 medications? Our directory lists 93 verified providers serving Scottsdale, Arizona (246,170 residents · 33.3% adult obesity).

Each clinic below offers GLP-1 weight-loss medications including Ozempic, Wegovy, Mounjaro, and Zepbound. Compare ratings, services, and pricing — then book directly or via our partner directory at GLP1Maps.com.

Find Your Clinic ↓Browse Full Directory →

Top 10 GLP-1 Clinics in Scottsdale

4.8

Scottsdale Weight Loss Center — Dr. Craig Primack & Dr. Robert Ziltzer lead Arizona’s premier physician-supervised GLP-1 practice. Offers Ozempic, Mounjaro, Wegovy, and Zepbound. 4 Valley locations. 5.0H

OzempicWegovyMounjaroZepboundIn-Person
4.6

Craft MD (Dr. Randall Craft) — Expert GLP-1 team with years of Arizona experience. Combines semaglutide and tirzepatide with MIC shots and nutritional guidance for comprehensive weight management. 4.8H

OzempicMounjaroIn-Person

Pricing: $400–$750/mo

More GLP-1 Resources

Independent network of GLP-1 resources serving Scottsdale and patients across the U.S.

What to Look for in a GLP-1 Clinic

Choosing the right GLP-1 provider in Scottsdale matters. Look for clinics that offer:

GLP-1 Medications Explained

GLP-1 receptor agonists work by mimicking a hormone that regulates appetite and blood sugar. The main options:

Cost & Insurance in Arizona

AHCCCS (Arizona Medicaid) covers GLP-1 for diabetes; weight-loss requires prior authorization.

For state regulation info, see the Arizona Medical Board.

Frequently Asked Questions

How many GLP-1 clinics are in Scottsdale?

Our directory lists 93 verified GLP-1 clinics in the Scottsdale area, with rankings based on patient reviews, services offered, and verified provider status.

Does insurance cover GLP-1 medications in Arizona?

AHCCCS (Arizona Medicaid) covers GLP-1 for diabetes; weight-loss requires prior authorization.

Are compounded GLP-1 medications still available?

Following the FDA's April 2026 503B ruling, compounded semaglutide and tirzepatide are no longer available from most U.S. pharmacies. Most clinics now prescribe FDA-approved Ozempic, Wegovy, Mounjaro, or Zepbound.